BioNTech SE (BNTXN)
BMV
Closed
Aug 21, 2026
Day's Range
1,960.0052 wk Range
1,456.73Profile - BNTXN - BioNTech SE
Profile
Mic Code
XMEX
Sector
Healthcare
Industry
Biotechnology
Employees
6.77K
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches designed to address hard-to-treat tumors. BioNTech also develops vaccine candidates and other immune-modulating treatments aimed at preventing or managing serious infectious diseases. Its work spans multiple platforms, including mRNA, protein-based therapies, and next-generation immunomodulators, reflecting a broad research and development base. BioNTech SE serves a central role in the biopharmaceutical market by advancing precision medicine approaches that combine molecular science with clinical development, supporting both preventative and therapeutic applications across global healthcare markets.
Profile Details
Type
American Depositary Receipt
Ceo
Dr. Ugur Sahin M.D.
Address
An der Goldgrube 12
City
Mainz
State
MI
Zip
55131
Country
Germany
Phone
49 6131 9084
Key Executives - BNTXN - BioNTech SE
Key executives
Cross Listings - BNTXN - BioNTech SE
Also listed on
The same company trading on other exchanges.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
